Navigation Links
Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40.
Date:7/24/2014

n, a 3% increase from the same period in 2013.  Organic sales growth for the first six months of 2014 was 2%.  Changes in foreign currency exchange rates increased reported sales growth by 1%.

In the second quarter of 2014, reported sales of the Research business unit ($357 million in sales, 51% of overall sales) grew by 1% from the second quarter of 2013.  Organic sales growth was flat, and changes in foreign currency exchange rates increased sales by 1%.

Research sales in the Academic/Government/Hospitals segment declined low single digits from the same period last year.  While U.S. sales showed improvement from the first quarter, academic sales were weaker in both the EMEA and APAC regions.  Organic sales growth in the Pharma segment was flat in the second quarter with low single-digit growth in the U.S. and EMEA.  Sales by our dealers grew in the low-to-mid single digit range.

Reported sales of the Applied business unit ($172 million in sales, 24.5% of overall sales) increased by 7% over the second quarter of 2013.  Organic sales growth was 6% and changes in foreign currency exchange rates increased sales by 1%.  Organic sales growth in the Diagnostics and Testing segment was double digits with contribution from all geographies, led by very strong performance in the APAC region.  Organic sales growth in the Industrial segment was in the low single digits.

Reported sales of the SAFC Commercial business unit ($172 million in sales, 24.5% of overall sales) grew by 2% over the second quarter of 2013.  Organic sales growth was 1%.  Changes in foreign currency exchange rates increased sales by 2%, and divestitures reduced reported sales by 1%.

Organic sales growth in the Life Science Products segment declined low-to-mid single digits, primarily due to changes in the timing of delivery of several large contract manufacturing orders.  Biopharma material sales continued to expe
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
2. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
3. Sigma-Aldrich Corporation To Present At Upcoming Investor Conferences
4. Sigma-Aldrich Enhances Customer Focus in China - Unveils Dynamic New Website and Expands Product Offering Through Vetec Brand
5. Sigma-Aldrich (NASDAQ: SIAL) Declares $0.20 Quarterly Dividend
6. Sigma-Aldrich Aligns Into Three New Market-Focused Business Units
7. Sigma-Aldrich Reports Record Full Year 2012 Results. Reports Q4 2012 Diluted EPS Of $0.96. Q4 2012 Sales Increased 7%. Full Year 2012 Adjusted Diluted EPS Was $3.85. Expects Full Year 2013 Adjusted Diluted EPS To Increase To $4.10 - $4.20.
8. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
9. Sigma-Aldrich Announces Q1 2013 Earnings Conference Call
10. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2013 Sales And EPS Of $675 Million And $1.01, Respectively, Both Record Quarterly Highs. Reaffirms Full Year 2013 Diluted Adjusted EPS Outlook Of $4.10 To $4.20.
11. Sigma-Aldrich Corporation Declares $0.215 Per Share Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Following a bipartisan vote in the House ... the Medicare DMEPOS Competitive Bidding Improvement Act of ... released a statement praising the Committee,s work and ... "Today,s mark-up of the Competitive Bidding ... Committee is a critical step forward for this ...
(Date:2/27/2015)... 27, 2015 An aggressive campaign to reduce ... rate of infection with a dangerous drug-resistant bacteria at ... Clostridium difficile, or C.diff, is a bacterium that can ... the colon. A recent article in the New England ... in the United States " asserts ...
(Date:2/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), ... for its first quarter ended December 31, 2014. ... 2014, revenue was $1,336,685. Operating expenses were $1,063,393.  Net ... share.  Covalon,s President and CEO, ... the significant progress we have made over the past ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
...  Boston Scientific Corporation (NYSE: BSX ) ... Chromium Coronary Stent System demonstrated non-inferior results in ... at one year compared to the PROMUS Element™ ... First Human Use Trial.  The trial reported one-year ...
... is pleased to announce the acquisition of Assured Packaging, ... custom manufacturer of aerosols for the health and beauty ... Assured Packaging acquisition and the purchase of K-G Spray-Pak ... most diversified custom aerosol filler in Canada. ...
Cached Medicine Technology:One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 2One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 3One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 4One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 5One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 6PLZ Aeroscience Acquires Assured Packaging 2
(Date:3/1/2015)... 2015 Women’s Excellence now offers ... (OAB) symptoms, such as a strong need to urinate with ... medication (anticholinergic) does not work well enough or cannot be ... another approach to targeting the source of OAB, the bladder ... and bladder muscle, blocking the signals that trigger OAB. ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Researchers say ... that so many sheet metal workers contract malignant mesothelioma. ... new report on its website. Click here to ... for Construction Research and Training monitored 17,345 sheet metal ... disproportionate number of them died of mesothelioma or ...
(Date:3/1/2015)... The number of transvaginal mesh lawsuits ... few weeks in two New Jersey litigations where attorneys ... Firm announces. , A Case List updated on ... County proceeding established for products manufactured by Johnson & ... earlier, when 90 fewer cases had been centralized. Additionally, ...
(Date:3/1/2015)... Barrel Mill ” was featured on NewsWatch as part of ... latest and coolest technology products and services available to consumers. ... conducted the review and shared with viewers how this oak ... Distillation of Alcohol, it's understood that oak is essential for ... that’ll help anyone achieve a barrel aged alcohol without having ...
(Date:2/28/2015)... The MCA Youth Empowerment Conference aims ... platform and gears towards the goal for a better ... group talks in smaller groups will be held after ... Development, Leadership, Entrepreneurship, Healthcare, Social and Volunteerism, Women and ... youths. , Young adults aged between 18-30 ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4
... front of TV, computer linked to less bonding with peers, ... Too much time in front of computers or televisions increases ... parents and peers, a new study suggests. , The researchers ... who provided details about how they spent their free time ...
... resulting aspirin therapy, may not be needed for healthier patients ... study raises questions about the value of both the ankle-brachial ... blood vessel problems in the legs, and the common practice ... ankle-brachial index (ABI) measures blood pressure in the arm and ...
... ... ... ... ...
... , ... ... , , ... ...
... ... ... ... ...
... , ... , ... , , , , ... ...
Cached Medicine News:Health News:Screen Time May Take a Toll on Kids' Relationships 2Health News:Study Questions Value of Test for Peripheral Artery Disease 2Health News:Study Questions Value of Test for Peripheral Artery Disease 3Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 2Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 3Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 4Health News:IDEXX Laboratories Elects Joseph Vumbacco as Director 2Health News:IDEXX Laboratories Elects Joseph Vumbacco as Director 3Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 2Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 3Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 4Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 5Health News:AMA Honors Maine Governor John Baldacci With Top Government Service Award 2Health News:AMA Honors Maine Governor John Baldacci With Top Government Service Award 3
... Liquichek Qualitative Urine Toxicology Control is ... qualitative rapid urine drug screen panels, including ... (DOA) test kits like Bio-Rad TOX/See, Biosite ... includes qualitative results (+/) for popular kits ...
... Stain is an aqueous new ... in manual methods of reticulocyte ... a one year shelf life ... can be used in conjunction ...
... Liquichek ToRCH Plus IgM ... potential problems in your ToRCH ... affect your test results. Liquichek ... the perfect complement to Liquichek ...
... Liquichek ToRCH Plus Control is ... to monitor the performance of ... instruments and assays. A weak ... allow you to monitor the ...
Medicine Products: